NEWS


2022

November 27, 2022

SurgiVance names Board of Directors and Advisory Board

SurgiVance: developing the simple, robust confocal optics for the cellular and nuclear resolution pathology requires. The software [see reference 2] enhances the image to improve surgeon/pathologist experience and potentially leverage AI.

After a rigorous selection process, SurgiVance has appointed its first Advisory Board and its first Board of Directors, with a mission to anchor SurgiVance to definitive standards in microscopy and medicine, with an eye for innovation.

Read more

July 7, 2022

Surgivance Has Been Awarded a Patent On a Solid-state Confocal Microscope.

SurgiVance has been awarded a #patent on a solid-state confocal #microscope recently. This will lead to robust, microscopic #imaging that we HOPE (no claim!) will advance  #histopathology as a small, durable, inexpensive but effective means of “direct-to-digital” pathological #analysis not only for the current #pathology market but also to create new #markets delivering #cancertreatment to rural and underserved communities that don’t have access to pathology yet. Go #imagingsolutions & #AI !!!  This is the result of our #nih an #nsf #sbir awards advancing this #medtech.

Read more

January 13, 2022

SurgiVance Inc. Awarded Competitive Grant from the National Science Foundation

New York, NY, January 10, 2022 – SurgiVance Inc. has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $256,000 to conduct research and development (R&D) work on digitizing the pathologist in the operating room. Combining biophysical optics and imaging with machine learning, SurgiVance aims to revolutionize digital health by advancing pathology, which is the way we diagnose diseases in order to treat them better.

Our engineering approach may lead to better and faster treatments. “NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering,” said Andrea Belz, Division Director of the Division of Industrial Innovation and Partnerships at NSF. “With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremendous needs.”

SurgiVance C.E.O. Daniel Gareau is optimistic about the future of digital pathology, given recent advances in optics and imaging. “This award will help SurgiVance proceed to hopefully achieve a Phase II NSF SBIR award of $1M which will complement the >$1M seed funding we have raised thus far,” said Dr. Gareau.

 


2020

July 31, 2020

SurgiVance™ Awarded SBIR from NCI/NIH

March 5, 2020

Ex vivo confocal microscopy: revolution in fast pathology in dermatology

Business Inquiries

SurgiVance™, Inc.
310 East 67th St.
Suite 2-91
New York, NY 10065
info@surgivance.com
+1-503-708-7078

Careers

SurgiVance™ is currently looking for engineers with expertise in opto-mechanics, deep-learning, or image recognition experience.

Please send your CV to info@surgivance.com.


SurgiVance is supported by the National Science Foundation and the National Institutes of Health

© 2022 SurgiVance™, Inc.
*SurgiVance™ has not yet been reviewed by the FDA and may not be used to manage patient care.